Table 2. Treatment-related adverse events in patients receiving an anti-PD-1 antibody plus lenvatinib.

TRAEs	Any grade, n (%)	Grade ≥3, n (%)
Appetite loss	20 (43.5)	4 (8.7)
Hypothyroidism	20 (43.5)	1 (2.2)
Hypertension	17 (36.9)	3 (6.5)
Fatigue	16 (34.8)	0
Diarrhea	12 (26.1)	2 (4.3)
Dysphonia	10 (21.7)	0
Weight loss	9 (19.6)	0
Hand-foot syndrome	8 (17.4)	0
Proteinuria	8 (17.4)	1 (2.2)
Hemorrhage	–	5 (10.9)
Immune pneumonia	–	2 (4.3)
Immune enteritis	–	1 (2.2)
Immune hepatitis	–	1 (2.2)
Rash	–	1 (2.2)
Shoulder pain	–	1 (2.2)
Thrombocytopenia	–	1 (2.2)

Table contains any TRAE reported in >5 (10%) patients and any TRAE ≥ grade 3. TRAEs, treatment-related adverse events.